deamidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-13 and is reviewed periodically as new material appears.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Dual agonism at the GIP and GLP-1 receptors underlies the observed pharmacology. Activation of GLP-1 receptors raises glucose-dependent insulin release, lowers glucagon secretion, slows gastric emptying and reduces appetite. GIP receptor activation contributes additional effects on adipose tissue and on energy balance, and the combined action on appetite appears larger than either pathway alone in animal models. Signalling bias and the relative contribution of each receptor arm to weight-related effects remain areas of active investigation.
Structure-activity work shows that fatty acid length, linker chemistry and the position of acylation all influence albumin affinity and receptor potency. Plasma protein binding exceeds 99 percent, which restricts distribution and slows renal clearance. Degradation proceeds largely through general proteolysis and fatty acid oxidation rather than cytochrome P450 metabolism, so exposure to common oxidative drug interactions is limited. Whether these clearance routes vary meaningfully between individuals is not fully established.
Long-term storage of lyophilised peptide powder is generally at minus twenty degrees Celsius or colder, with desiccant and protection from light. Short-term storage at two to eight degrees Celsius is common during active use. In solution, stability depends strongly on pH, concentration, and the presence of preservatives, and hydrolysis or aggregation can develop over weeks. Published stability data specific to this molecule are limited, so recommended conditions for research material are usually extrapolated from general peptide handling practice rather than from a dedicated study.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
One of the most common methods of delivering vaccines into the human body is injection. The development of new delivery systems raises the hope of vaccines that are safer and more efficient to deliver and administer. Lines of research include liposomes and ISCOM (immune stimulating complex).
== Habitat == The Turkestan cockroach is primarily an outdoor insect, not known as an aggressive indoor pest, unlike some cockroach species such as the German and brown-banded cockroaches, though it will inhabit areas around dwellings where shelter can be found. However, in specific localities or tropical locations, it can become a significant indoor pest. Of occasional indoor interlopers, males are more commonly encountered than females, due to their ability to fly and an attraction to lights. In Arabia, it lives beneath stones in damp hollows, desert farms, and wadis, feeding primarily at night.
=== Binding === DCBQ is an electrophilic compound, so it can bind in the human body to multiple nucleophilic compounds. DCBQ can, for instance, react with GSH, substituting the Cl groups for the GS group. DCBQ is thus being dechlorinated and can undergo Michael addition with GSH, resulting in more glutathionylated products. The second Cl group can also be removed from the compound when reacting with another GSH molecule. DCBQ can also undergo redox reactions when reacting with an electron, forming radicals. These radicals can also react with GSH, forming more conjugation products. DCBQ can also react with amino acids. When DCBQ was brought in contact with amino acids, the DCBQ was quickly removed, suggesting that the DCBQ reacted with the amino acids. DCBQ binds to the DNA via H-bonds, a non-covalent interaction. Because of its hydrophobicity, DCBQ might be intercalated between nucleotides in a double-stranded DNA molecule [source]. This intercalation might lead to increased access to the nucleotides, possibly leading to even more oxidative damage in the DNA. Amino acids can also covalently bind to DCBQ. The amino acids undergo nucleophilic substitution with both DCBQ and DCBQ-OH, the product of DCBQ hydrolysis. Proteins can be bound by DCBQ covalently via cysteine or lysine residues. Catechins, which are naturally present in for instance green tea, can competitively bind to DCBQ, reducing the amount of proteins bound to DCBQ [16]. The proteins are covalently modified when bound to DCBQ, which might change the stability and alter the function of the protein.
Sources: en.wikipedia.org
He sent Signoret specimens of American grape lice, which Signoret concluded – in 1870, while he was besieged in Paris during the Franco-Prussian War – were indeed identical to French grape lice. Meanwhile, Planchon and Lichtenstein had found vines with afflicted leaves; lice that were transferred from those leaves to the roots of healthy vines attached themselves to the vines' roots as other French grape lice did. Also in 1870, Riley discovered that American grape lice wintered on American grape vines' roots, which the insects damaged, albeit less than in the case of French vines. Riley repeated Planchon and Lichtenstein's experiment using American grape vines and American grape lice, with similar results. Thus the identity of the French and American grape lice was proven. Nevertheless, for another three years, a powerful majority in France argued that Phylloxera was not the cause of vine disease; instead, vines that were already sickly became infested with Phylloxera. Thus, in their opinion, Phylloxera was merely a consequence of the "true" disease, which remained to be found. Regardless, Riley had discovered American grape varieties that were especially resistant to Phylloxera, and by 1871, French farmers began to import them and to graft French vines onto the American rootstock. (Leo Laliman had suggested importing American vines as early as 1869, but French farmers were reluctant to abandon their traditional varieties.
Elton John plays the final UK concert of his farewell tour at Glastonbury 2023, headlining the Pyramid Stage on the festival's final day. 26 June A two-year BBC investigation into the 1993 murder of Stephen Lawrence identifies a sixth suspect who was not charged at the time and is now deceased. Banking giant HSBC announces that it will vacate its 45-storey tower at 8 Canada Square in Canary Wharf and establish a smaller headquarters, possibly in the City of London, when its current lease expires in 2027. The move is attributed to an increase in remote work and less need for in-person office work. Prince William and Geri Horner announce the launch of Homewards, a five-year project aimed at reducing the number of homeless people in the UK. The National Cancer Research Institute announces that it will be closing, amid concerns over its funding. 27 June Boots announces plans to close 300 of its outlets over the next years, saying it will close stores in close proximity to other branches. A report compiled by the Independent Commission for Equity in Cricket (ICEC) says racism, sexism, classism and elitism are "widespread" in English and Welsh cricket. 28 June Daniel Korski withdraws as the Conservative Party's candidate for the 2024 London mayoral election after being accused of groping by novelist and TV producer Daisy Goodwin. A BBC News investigation finds that paedophiles are using Stable Diffusion, a piece of artificial intelligence software, to create lifelike images of child sexual abuse, which are then being distributed through platforms such as Patreon.
== Uniformity == The chemical processing and synthesis of high performance technological components for the private, industrial and military sectors requires the use of high purity ceramics, polymera, glass-ceramics, and composite materials. In condensed bodies formed from fine powders, the irregular sizes and shapes of nanoparticles in a typical powder often lead to non-uniform packing morphologies that result in packing density variations in the powder compact. Uncontrolled agglomeration of powders due to attractive van der Waals forces can also give rise to in microstructural inhomogeneities. Differential stresses that develop as a result of non-uniform drying shrinkage are directly related to the rate at which the solvent can be removed, and thus highly dependent upon the distribution of porosity. Such stresses have been associated with a plastic-to-brittle transition in consolidated bodies, and can yield to crack propagation in the unfired body if not relieved. In addition, any fluctuations in packing density in the compact as it is prepared for the kiln are often amplified during the sintering process, yielding inhomogeneous densification. Some pores and other structural defects associated with density variations have been shown to play a detrimental role in the sintering process by growing and thus limiting end-point densities. Differential stresses arising from inhomogeneous densification have also been shown to result in the propagation of internal cracks, thus becoming the strength-controlling flaws.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
Solid material is normally kept frozen at about -20 degrees Celsius, desiccated and protected from light. Solutions are held cold and used within a defined window because degradation products accumulate over time.